CRH Medical Corporation (NYSEAMERICAN: CRHM) is a U.S.-based medical device company focused on the development and commercialization of minimally invasive technologies for the diagnosis and treatment of hemorrhoidal disease and related anorectal conditions. Headquartered in East Hanover, New Jersey, the company’s primary mission is to advance patient care through outpatient solutions that reduce pain, recovery time and overall procedure costs compared with traditional surgical approaches.
The company’s flagship offering is the CRH O’Regan System, a proprietary rubber band ligation platform originally introduced in the 1960s and continually refined over successive generations. The system enables physicians to perform hemorrhoid banding in an office or ambulatory surgery center setting without the need for anesthesia in most cases. In addition to ligators and banding devices, CRH Medical provides a suite of ancillary instruments and disposables—such as proctoscopes, obturators and positioning accessories—designed to streamline procedural workflow and enhance patient comfort.
Beyond its core device business, CRH Medical has expanded its footprint through the operation and acquisition of gastroenterology-focused outpatient centers. These facilities deliver endoscopic diagnostics and therapeutic services, reinforcing the company’s commitment to comprehensive care in the field of proctology and related specialties. By integrating device innovation with clinical service offerings, CRH Medical seeks to create a continuum of care that spans from initial diagnosis through minimally invasive treatment.
CRH Medical maintains a global distribution network covering North America, Europe, Asia Pacific and select emerging markets. The company invests in ongoing research and development initiatives aimed at extending its product portfolio into adjacent indications, including treatment of anal fissures and other benign pelvic floor disorders. Leadership at CRH Medical combines clinical experience with commercial expertise to navigate regulatory pathways and foster partnerships with healthcare providers, ensuring continued adoption of its technologies in both established and growing markets.
AI Generated. May Contain Errors.
